Androgen dynamics and serum PSA in patients treated with abiraterone acetate

BACKGROUND: We analyzed the potential of abiraterone acetate (henceforth abiraterone) to reduce androgen levels below lower limits of quantification (LLOQ) and explored the association with changes in PSA decline in metastatic castration-resistant prostate cancer (mCRPC) patients. METHODS: COU-AA-30...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Ryan, C J, Peng, W, Kheoh, T, Welkowsky, E, Haqq, C M, Chandler, D W, Scher, H I, Molina, A
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group 2014
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4020277/
https://ncbi.nlm.nih.gov/pubmed/24637537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/pcan.2014.8
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg